Top

Published in:

01-06-2006

Implication of the BRCA2 and Putative “BRCA3” Genes in Dukes’ Stage C, Replication Error–Negative Colon Cancer

Authors: Nala S. Sivarajasingham, MD, Lynn Cawkwell, PhD, Richard P. Baker, MD, Sara L. O’Kane, BSc, Edward F. Smyth, MD, Jonathan V. T. Tilsed, MD, Mark B. Watson, PhD, John Greenman, PhD, John R. T. Monson, MD

Published in: Annals of Surgical Oncology | Issue 6/2006

Abstract

Background

Although BRCA genes have been implicated in certain tumors, particularly breast tumors, their role in colon tumorigenesis has not been fully explored. We aimed to investigate the association of the BRCA2 and putative “BRCA3” genes in a homogeneous series of right-sided colon cancer specimens.

Methods

Twenty-three Dukes’ stage C, replication error–negative carcinomas were selected from patients with right-sided colon cancer. After histological examination and microdissection, DNA was extracted from normal colon and carcinoma from each patient. Five microsatellite markers spanning the region of BRCA2 and BRCA3 on chromosome 13 (D13S218, D13S219, D13S165, D13S156, and D13S160) and two markers intragenic to BRCA2 and BRCA3 (D13S171 and D13S1308, respectively) were used. Polymerase chain reaction products were analyzed by using a fluorescent allele imbalance assay.

Results

Markers demonstrating the highest allelic imbalance were D13S1308 (53%), D13S171 (33%), and D13S160 (37%).

Conclusions

The intragenic markers D13S1308 (BRCA3) and D13S171 (BRCA2) on chromosome 13 demonstrated a high frequency of allelic imbalance in primary colon carcinoma. This suggests an involvement of BRCA2 and putative BRCA3 in colon tumorigenesis in right-sided, replication error–negative, Dukes’ stage C cancers. Further studies are needed to confirm the precise role of these genes, and any prognostic significance, in colon cancer.

Vogelstein B, Fearon ER, Kern SE, et al. Allelotype of colorectal carcinomas. Science 1989;244:207–11PubMed

Vogelstein B, Fearon ER, Hamilton SR, et al. Genetic alterations during colorectal-tumor development. N Engl J Med 1988;319:525–32PubMedCrossRef

Fearon ER, Vogelstein B. A genetic model for colorectal tumorigenesis. Cell 1990;61:759–67CrossRefPubMed

Tomlinson I, Ilyas M, Johnson V, et al. A comparison of the genetic pathways involved in the pathogenesis of three types of colorectal cancer. J Pathol 1998;184:148–52CrossRefPubMed

Fearon ER, Hamilton SR, Vogelstein B. Clonal analysis of human colorectal tumors. Science 1987;238:193–7PubMed

Ried T, Knutzen R, Steinbeck R, et al. Comparative genomic hybridization reveals a specific pattern of chromosomal gains and losses during the genesis of colorectal tumors. Genes Chromosomes Cancer 1996;15:234–45CrossRefPubMed

Nakao K, Shibusawa M, Ishihara A, et al. Genetic changes in colorectal carcinoma tumors with liver metastases analyzed by comparative genomic hybridization and DNA ploidy. Cancer 2001;91:721–6CrossRefPubMed

Lothe RA, Fossli T, Danielsen HE, et al. Molecular genetic studies of tumor suppressor gene regions on chromosomes 13 and 17 in colorectal tumors. J Natl Cancer Inst 1992;84:1100–8PubMed

Meijer GA, Hermsen MA, Baak JP, et al. Progression from colorectal adenoma to carcinoma is associated with non-random chromosomal gains as detected by comparative genomic hybridisation. J Clin Pathol 1998;51:901–9PubMedCrossRef

10.

Ookawa K, Sakamoto M, Hirohashi S, et al. Concordant p53 and DCC alterations and allelic losses on chromosomes 13q and 14q associated with liver metastases of colorectal carcinoma. Int J Cancer 1993;53:382–7PubMed

11.

Sivarajasingham NS, Baker R, Tilsed JV, Greenman J, Monson JR, Cawkwell L. Identifying a region of interest in site- and stage-specific colon cancer on chromosome 13. Ann Surg Oncol 2003;10:1095–9CrossRefPubMed

12.

Fasouliotis SJ, Schenker JG. BRCA1 and BRCA2 gene mutations: decision-making dilemmas concerning testing and management. Obstet Gynecol Surv 2000;55:373–84CrossRefPubMed

13.

Kainu T, Juo SH, Desper R, et al. Somatic deletions in hereditary breast cancers implicate 13q21 as a putative novel breast cancer susceptibility locus. Proc Natl Acad Sci U S A 2000;97:9603–8CrossRefPubMed

14.

Ford D, Easton DF, Stratton M, et al. Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium. Am J Hum Genet 1998;62:676–89CrossRefPubMed

15.

Vehmanen P, Friedman LS, Eerola H, et al. Low proportion of BRCA1 and BRCA2 mutations in Finnish breast cancer families: evidence for additional susceptibility genes. Hum Mol Genet 1997;6:2309–15CrossRefPubMed

16.

Narod SA, Foulkes WD. BRCA1 and BRCA2: 1994 and beyond. Nat Rev Cancer 2004;4:665–76CrossRefPubMed

17.

Gorgoulis VG, Kotsinas A, Zacharatos P, et al. Association of allelic imbalance at locus D13S171 (BRCA2) and p53 alterations with tumor kinetics and chromosomal instability (aneuploidy) in nonsmall cell lung carcinoma. Cancer 2000;89:1933–45CrossRefPubMed

18.

Tavtigian SV, Simard J, Rommens J, et al. The complete BRCA2 gene and mutations in chromosome 13q-linked kindreds. Nat Genet 1996;12:333–7CrossRefPubMed

19.

Moynahan ME, Cui TY, Jasin M. Homology-directed DNA repair, mitomycin-c resistance, and chromosome stability is restored with correction of a BRCA1 mutation. Cancer Res 2001;61:4842–50PubMed

20.

Moynahan ME, Pierce AJ, Jasin M. BRCA2 is required for homology-directed repair of chromosomal breaks. Mol Cell 2001;7:263–72CrossRefPubMed

21.

Davies AA, Masson JY, McIlwraith MJ, et al. Role of BRCA2 in control of the RAD51 recombination and DNA repair protein. Mol Cell 2001;7:273–82CrossRefPubMed

22.

Pellegrini L, Yu DS, Lo T, et al. Insights into DNA recombination from the structure of a RAD51-BRCA2 complex. Nature 2002;420:287–93CrossRefPubMed

23.

Thompson D, Szabo CI, Mangion J, et al. Evaluation of linkage of breast cancer to the putative BRCA3 locus on chromosome 13q21 in 128 multiple case families from the Breast Cancer Linkage Consortium. Proc Natl Acad Sci U S A 2002;99:827–31CrossRefPubMed

24.

Tong D, Schuster E, Czerwenka K, Leodolter S, Zeillinger R. Loss of heterozygosity on chromosome 13q: suggestion of a candidate tumor suppressor gene in sporadic breast cancer. Breast Cancer Res Treat 2004;83:143–8CrossRefPubMed

25.

Lindblom A. Different mechanisms in the tumorigenesis of proximal and distal colon cancers. Curr Opin Oncol 2001;13:63–9CrossRefPubMed

26.

Kapiteijn E, Liefers GJ, Los LC, et al. Mechanisms of oncogenesis in colon versus rectal cancer. J Pathol 2001;195:171–8CrossRefPubMed

27.

Distler P, Holt PR. Are right- and left-sided colon neoplasms distinct tumors? Dig Dis 1997;15:302–11PubMedCrossRef

28.

Cawkwell L, Gray S, Murgatroyd H, et al. Choice of management strategy for colorectal cancer based on a diagnostic immunohistochemical test for defective mismatch repair. Gut 1999;45:409–15PubMedCrossRef

29.

Cawkwell L, Bell SM, Lewis FA, Dixon MF, Taylor GR, Quirke P. Rapid detection of allele loss in colorectal tumors using microsatellites and fluorescent DNA technology. Br J Cancer 1993;67:1262–7PubMed

30.

Cawkwell L, Lewis FA, Quirke P. Frequency of allele loss of DCC, p53, RBI, WT1, NF1, NM23 and APC/MCC in colorectal cancer assayed by fluorescent multiplex polymerase chain reaction. Br J Cancer 1994;70:813–8PubMed

31.

Skotheim RI, Diep CB, Kraggerud SM, Jakobsen KS, Lothe RA. Evaluation of loss of heterozygosity/allelic imbalance scoring in tumor DNA. Cancer Genet Cytogenet 2001;127:64–70CrossRefPubMed

32.

Fujiwara Y, Emi M, Ohata H, et al. Evidence for the presence of two tumor suppressor genes on chromosome 8p for colorectal carcinoma. Cancer Res 1993;53:1172–4PubMed

33.

Garcia JM, Rodriguez R, Dominguez G, et al. Prognostic significance of the allelic loss of the BRCA1 gene in colorectal cancer. Gut 2003;52:1756–63CrossRefPubMed

Title: Implication of the BRCA2 and Putative “BRCA3” Genes in Dukes’ Stage C, Replication Error–Negative Colon Cancer
Authors: Nala S. Sivarajasingham, MD
Lynn Cawkwell, PhD
Richard P. Baker, MD
Sara L. O’Kane, BSc
Edward F. Smyth, MD
Jonathan V. T. Tilsed, MD
Mark B. Watson, PhD
John Greenman, PhD
John R. T. Monson, MD
Publication date: 01-06-2006
Publisher: Springer-Verlag
Published in: Annals of Surgical Oncology / Issue 6/2006
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI: https://doi.org/10.1245/ASO.2006.05.021

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Implication of the BRCA2 and Putative “BRCA3” Genes in Dukes’ Stage C, Replication Error–Negative Colon Cancer

Abstract

Background

Methods

Results

Conclusions

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 6/2006

The Surgeon-Patient Interaction in Older Women With Breast Cancer: What Are the Determinants of a Helpful Discussion?

Adjuvant Treatment of Stage II Colon Cancer: Is There a True No-Chemotherapy Group?

Current Issues in Adjuvant Treatment of Stage II Colon Cancer

Expression of Interleukin 11 and Its Receptor and Their Prognostic Value in Human Breast Cancer

Completion Lymphadenectomy for Melanoma Patients With a Positive Sentinel Node Biopsy Remains Standard of Care

Trends in Hospital and Surgeon Volume and Operative Mortality for Cancer Surgery